- Home
- MNPR vs FSTR Comparison
MNPR vs FSTR Comparison
Compare MNPR & FSTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNPR
- FSTR
- Stock Information
- Founded
- MNPR 2014
- FSTR 1902
- Country
- MNPR United States
- FSTR United States
- Employees
- MNPR N/A
- FSTR N/A
- Industry
- MNPR Biotechnology: Pharmaceutical Preparations
- FSTR Metal Fabrications
- Sector
- MNPR Health Care
- FSTR Industrials
- Exchange
- MNPR Nasdaq
- FSTR Nasdaq
- Market Cap
- MNPR 248.8M
- FSTR 239.1M
- IPO Year
- MNPR 2019
- FSTR N/A
- Fundamental
- Price
- MNPR $66.64
- FSTR $27.84
- Analyst Decision
- MNPR Strong Buy
- FSTR Hold
- Analyst Count
- MNPR 11
- FSTR 1
- Target Price
- MNPR $68.60
- FSTR $25.00
- AVG Volume (30 Days)
- MNPR 44.1K
- FSTR 30.8K
- Earning Date
- MNPR 11-07-2025
- FSTR 11-06-2025
- Dividend Yield
- MNPR N/A
- FSTR N/A
- EPS Growth
- MNPR N/A
- FSTR 395.33
- EPS
- MNPR N/A
- FSTR 3.32
- Revenue
- MNPR N/A
- FSTR $506,999,000.00
- Revenue This Year
- MNPR N/A
- FSTR $4.25
- Revenue Next Year
- MNPR N/A
- FSTR $3.61
- P/E Ratio
- MNPR N/A
- FSTR $8.32
- Revenue Growth
- MNPR N/A
- FSTR N/A
- 52 Week Low
- MNPR $3.90
- FSTR $17.16
- 52 Week High
- MNPR $68.18
- FSTR $29.78
- Technical
- Relative Strength Index (RSI)
- MNPR 80.24
- FSTR 65.92
- Support Level
- MNPR $42.51
- FSTR $26.99
- Resistance Level
- MNPR $45.78
- FSTR $27.96
- Average True Range (ATR)
- MNPR 4.36
- FSTR 0.91
- MACD
- MNPR 2.91
- FSTR 0.08
- Stochastic Oscillator
- MNPR 95.65
- FSTR 75.42
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
About FSTR L.B. Foster Company
L.B. Foster Co is a U.S-based firm engaged in the manufacturing, fabrication, and distribution of products and services, especially for the rail, construction, energy, and utility industries. The company operates its business through two segments: Rail Technologies and Services and Infrastructure Solutions. Its principal business activity involves providing new and used rail, trackwork, and accessories, producing concrete railroad ties, insulated rail joints, power rail, track fasteners, cover boards, and sales of sells and rents steel sheet piling, H-bearing pile, and other piling products for foundation and earth retention requirements. It generates the majority of its revenues from the Rail Technologies and Services segment.